PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2058579
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2058579
In Vitro Diagnostics (IVD) Quality Control Market size was valued at US$ 1,660.5 Million in 2025, expanding at a CAGR of 6.1% from 2026 to 2033.
In Vitro Diagnostics (IVD) Quality Control refers to the set of materials, processes, and procedures used to ensure that diagnostic tests performed in laboratories produce accurate, consistent, and reliable results. It involves the use of control samples that are tested alongside patient specimens to verify that instruments, reagents, and testing methods are functioning correctly. This helps laboratories detect errors early, maintain testing standards, and support correct clinical decision-making. It is an essential part of diagnostic workflows, especially in hospitals, reference laboratories, and research settings where precision and repeatability of results are critical for patient care.
Government bodies such as China's National Medical Products Administration (NMPA), India's Central Drugs Standard Control Organization (CDSCO), and Japan's Ministry of Health, Labour and Welfare (MHLW) are actively strengthening guidelines for diagnostic testing and laboratory quality assurance. These regulatory efforts are encouraging healthcare providers to adopt structured quality control practices to ensure reliable test performance. International organizations such as the World Health Organization (WHO) also promote standardized laboratory practices for disease detection and public health surveillance. Collectively, these structures have helped foster more uniform conditions within laboratories and increased confidence in laboratory findings.
In Vitro Diagnostics (IVD) Quality Control Market- Market Dynamics
Rising focus on diagnostic accuracy and patient safety
The rising focus on diagnostic accuracy and patient safety is steadily strengthening demand for In Vitro Diagnostics (IVD) Quality Control solutions, as laboratories aim to minimize testing errors and ensure dependable clinical decisions. Governments outside the U.S. and Europe are reinforcing this direction through structured laboratory standards. For example, China's National Medical Products Administration (NMPA) has tightened approval and post-market surveillance requirements for diagnostic reagents, encouraging stronger quality verification practices.
In India, the regulatory body known as the Central Drugs Standard Control Organization (CDSCO) has been making efforts to tighten up regulation of in-vitro diagnostics by providing guidelines for testing protocols. On the industry side, Roche Diagnostics and Bio-Rad Laboratories provide integrated quality control systems that help laboratories maintain consistent calibration and reliable results, reinforcing patient safety and confidence in diagnostic reporting across clinical environments.
The Global In Vitro Diagnostics (IVD) Quality Control Market is segmented on the basis of Product and Service, Application, Manufacturer Type, End User, and Region.
In terms of manufacturing type, instrument-specific controls are likely to be a key segment due to their close alignment with automated analyzer systems and laboratory workflow precision requirements. These controls are designed to work directly with specific diagnostic instruments, helping laboratories maintain consistent calibration, reduce analytical variation, and ensure reliable test outputs. Their importance is increasing as laboratories shift toward high-throughput and automated testing environments where system compatibility becomes essential Moreover, Bio-Rad Laboratories offers control materials customized to the instruments that are commonly used in clinical chemistry and immunoassay test systems. This is additionally complemented by advances in laboratory automation championed by Thermo Fisher Scientific, whereby instrument standardization leads to improved workflow and accountability of results.
In Vitro Diagnostics (IVD) Quality Control Market- Geographical Insights
The geographical development of the In Vitro Diagnostics (IVD) Quality Control market is shaped by strict laboratory regulations, rising diagnostic test volumes, and increasing adoption of automated quality assurance systems across healthcare networks. Across global regions, North America and Asia-Pacific are expected to remain the most influential areas due to their strong regulatory frameworks, expanding clinical laboratory infrastructure, and continuous investments in diagnostic accuracy systems. North America maintains a strong position supported by regulatory oversight from agencies such as the U.S. Food and Drug Administration (FDA), Clinical Laboratory Improvement Amendments (CLIA) under the Centers for Medicare & Medicaid Services (CMS), and Health Canada, which collectively enforce strict quality control compliance in clinical laboratories. In addition, the U.S. Centers for Disease Control and Prevention (CDC) support laboratory quality standards and disease surveillance programs. In terms of companies, organizations like Roche Diagnostics and Thermo Fisher Scientific have enhanced laboratory QC ecosystems via automated diagnostic systems and data management integration capabilities, in light of laboratory adoption trends in line with regulatory requirements. The region continues to benefit from a highly structured diagnostic environment and widespread accreditation systems that sustain consistent demand for quality control products.
Asia-Pacific is also expected to maintain a strong influence due to the rapid expansion of hospital networks, increasing diagnostic awareness, and government-led healthcare modernization programs across countries such as China, India, and Japan. Regulatory bodies, including China's National Medical Products Administration (NMPA), India's Central Drugs Standard Control Organization (CDSCO), and Japan's Ministry of Health, Labour and Welfare (MHLW) are actively strengthening laboratory testing standards and external quality assessment systems to improve diagnostic reliability. Government-backed screening programs and rising investment in laboratory infrastructure continue to support demand for quality control solutions across the region. On the industry side, companies such as Sysmex Corporation and Abbott Laboratories are expanding their diagnostic portfolios with automated analyzers and standardized QC materials tailored for high-volume testing environments. Together, these factors position Asia-Pacific as a rapidly expanding hub for diagnostic quality assurance systems, supported by both public health initiatives and private sector innovation.
India In Vitro Diagnostics (IVD) Quality Control Market- Country Insights
India is gradually strengthening its position in the In Vitro Diagnostics (IVD) Quality Control market, supported by expanding diagnostic awareness, rising patient screening activities, and increasing reliance on laboratory-based healthcare services. The country's healthcare system is witnessing steady improvement in diagnostic infrastructure, where both urban hospitals and emerging diagnostic chains are focusing on accuracy, traceability, and standardization of test results. This shift is encouraging greater use of quality control materials and automated verification systems in clinical laboratories to reduce testing errors and improve reliability of outcomes.
The growth environment is also influenced by the wider adoption of advanced testing methods in pathology and molecular diagnostics, along with increasing outsourcing of laboratory services by smaller healthcare centers to larger reference labs. Rising focus on preventive healthcare and early disease detection is further supporting the need for consistent quality assurance practices in diagnostic workflows. In addition, growing digital integration in laboratories is helping improve data management and result validation processes. Collectively, these developments are creating a more structured and quality-focused diagnostic ecosystem in India.
The In Vitro Diagnostics (IVD) Quality Control market is shaped by the presence of multinational healthcare End User providers and specialized laboratory solution developers focusing on consistent testing accuracy and regulatory alignment. Companies including Bio-Rad Laboratories, Thermo Fisher Scientific, Randox Laboratories, and Roche Diagnostics strengthen their position through automated quality control products, digital laboratory connectivity, and broader assay portfolios. Products are supplied through hospital procurement channels, diagnostic laboratories, regional distributors, and direct service agreements. Manufacturers also focus on laboratory workflow efficiency, reagent stability, and compliance support to strengthen long-term customer relationships across clinical testing environments.
Industry participants continue expanding their presence through collaborations, acquisitions, and advanced diagnostic quality solutions. In March 2026, Abbott Laboratories completed the acquisition of Exact Sciences to strengthen its molecular diagnostics and cancer testing capabilities, supporting wider access to precision diagnostic solutions. In April 2026, QuidelOrtho finalized the acquisition of LEX Diagnostics, adding rapid PCR testing technologies to its diagnostic operations for faster laboratory-quality results. Such developments reflect how organizations are focusing on automation, rapid disease detection, and dependable testing standards to support healthcare providers and diagnostic laboratories in routine clinical decision-making
In March 2026, Integrated DNA Technologies introduced its first in vitro diagnostic next-generation sequencing assays under the Archer platform. The launch was designed to improve standardized oncology testing workflows while supporting laboratories with quality-focused and regulatory-aligned molecular diagnostic solutions.
In January 2026, Gentian Diagnostics entered an exclusive collaboration with a global diagnostics manufacturer to develop a novel diagnostic assay for integration into widely used clinical chemistry analyzer systems. The initiative is focused on strengthening automated assay performance, validation processes, and scalable in vitro diagnostic quality solutions for laboratory applications